An Open-Label, Phase 1 Trial to Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors ZAI Lab
Most Recent Events
- 24 Nov 2023 Status changed from active, no longer recruiting to completed.
- 30 Oct 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 09 Oct 2023 Planned initiation date changed from 1 Jun 2023 to 9 Oct 2023.